89bio to Participate in the 7th Annual Evercore HealthCONx Conference

GlobeNewswire

2024-11-27

SAN FRANCISCO, Calif., Nov. 26, 2024 (GLOBE NEWSWIRE) -- 89bio, Inc. (the “Company” or “89bio”) (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardiometabolic diseases, today announced that the Company’s Management will participate in a fireside chat at the 7^th Annual Evercore HealthCONx Conference on Tuesday, December 3, 2024 at 8:20 AM ET and participate in one-on-one investor meetings.

The webcast of the fireside chat will be accessible in the investor section of 89bio’s website. A replay of the webcast will be available for approximately 30 days following the conference.

About 89bio
89bio is a clinical-stage biopharmaceutical company dedicated to the development of best-in-class therapies for patients with liver and cardiometabolic diseases who lack optimal treatment options. The company is focused on rapidly advancing its lead candidate, pegozafermin, through clinical development for the treatment of metabolic dysfunction-associated steatohepatitis (MASH) and severe hypertriglyceridemia (SHTG). Pegozafermin is a specifically engineered, potentially best-in-class fibroblast growth factor 21 (FGF21) analog with unique glycoPEGylated technology that optimizes biological activity through an extended half-life. The company is headquartered in San Francisco. For more information, visit www.89bio.com or follow the company on LinkedIn.

Investor Contact:
Annie Chang
89bio, Inc.
investors@89bio.com

PJ Kelleher
LifeSci Advisors, LLC
617-430-7579
pkelleher@lifesciadvisors.com

Media Contact:
Sheryl Seapy
Real Chemistry
sseapy@realchemistry.com

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/2486205834"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2486205834\",edition:\"fundamental\",,,undefined,":{"share":"https://ttm.financial/m/news/2486205834?lang=zh_TW&edition=fundamental","thumbnail":"https://s.yimg.com/uu/api/res/1.2/OBcqXzIqiNQZbGfiTeetOA--~B/aD02ODt3PTE4MTthcHBpZD15dGFjaHlvbg--/https://media.zenfs.com/en/globenewswire.com/b32d53353b31091b62fe237e474ab39c","is_english":true,"pubTime":"2024-11-27 05:05","share_image_url":"https://static.laohu8.com/5f26f4a48f9cb3e29be4d71d3ba8c038","id":"2486205834","market":"us","top_or_hot":-1,"title":"89bio to Participate in the 7th Annual Evercore HealthCONx Conference","media":"GlobeNewswire","content":"<html><body><img hspace=\"5\" src=\"https://s.yimg.com/uu/api/res/1.2/hsWEdYc2moqhVRIbIMyAIA--/cT03NTthcHBpZD15dmlkZW9mZWVkczs-/https://media.zenfs.com/en/globenewswire.com/7c94eb6daca1318be34bd47ed183f8eb\" title=\"89biologo.png\" vspace=\"5\"/>\n<p>SAN FRANCISCO, Calif., Nov. 26, 2024 (GLOBE NEWSWIRE) -- 89bio, Inc. (the “Company” or “89bio”) (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardiometabolic diseases, today announced that the Company’s Management will participate in a fireside chat at the 7<sup>th</sup> Annual <a href=\"https://laohu8.com/S/EVR\">Evercore</a> HealthCONx Conference on Tuesday, December 3, 2024 at 8:20 AM ET and participate in one-on-one investor meetings.</p>\n<p>The webcast of the fireside chat will be accessible in the investor section of 89bio’s website. A replay of the webcast will be available for approximately 30 days following the conference.</p>\n<p><strong>About 89bio</strong><br/>89bio is a clinical-stage biopharmaceutical company dedicated to the development of best-in-class therapies for patients with liver and cardiometabolic diseases who lack optimal treatment options. The company is focused on rapidly advancing its lead candidate, pegozafermin, through clinical development for the treatment of metabolic dysfunction-associated steatohepatitis (MASH) and severe hypertriglyceridemia (SHTG). Pegozafermin is a specifically engineered, potentially best-in-class fibroblast growth factor 21 (FGF21) analog with unique glycoPEGylated technology that optimizes biological activity through an extended half-life. The company is headquartered in San Francisco. For more information, visit www.89bio.com or follow the company on LinkedIn.<br/></p>\n<p><strong>Investor Contact: </strong><br/>Annie Chang <br/>89bio, Inc.<br/>investors@89bio.com<br/><br/><br/><br/></p>\n<p>PJ Kelleher<br/>LifeSci Advisors, LLC<br/>617-430-7579<br/>pkelleher@lifesciadvisors.com<br/><br/><br/></p>\n<p><strong>Media Contact: </strong><br/>Sheryl Seapy<br/>Real Chemistry<br/>sseapy@realchemistry.com<br/><br/><br/></p>\n<br/></body></html>","source":"yahoofinance","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>89bio to Participate in the 7th Annual Evercore HealthCONx Conference</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n89bio to Participate in the 7th Annual Evercore HealthCONx Conference\n</h2>\n<h4 class=\"meta\">\n<p class=\"head\">\n<strong class=\"h-name small\">GlobeNewswire</strong><span class=\"h-time small\">2024-11-27 05:05</span>\n</p>\n</h4>\n</header>\n<article>\n<html><body><img hspace=\"5\" src=\"https://s.yimg.com/uu/api/res/1.2/hsWEdYc2moqhVRIbIMyAIA--/cT03NTthcHBpZD15dmlkZW9mZWVkczs-/https://media.zenfs.com/en/globenewswire.com/7c94eb6daca1318be34bd47ed183f8eb\" title=\"89biologo.png\" vspace=\"5\"/>\n<p>SAN FRANCISCO, Calif., Nov. 26, 2024 (GLOBE NEWSWIRE) -- 89bio, Inc. (the “Company” or “89bio”) (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardiometabolic diseases, today announced that the Company’s Management will participate in a fireside chat at the 7<sup>th</sup> Annual <a href=\"https://laohu8.com/S/EVR\">Evercore</a> HealthCONx Conference on Tuesday, December 3, 2024 at 8:20 AM ET and participate in one-on-one investor meetings.</p>\n<p>The webcast of the fireside chat will be accessible in the investor section of 89bio’s website. A replay of the webcast will be available for approximately 30 days following the conference.</p>\n<p><strong>About 89bio</strong><br/>89bio is a clinical-stage biopharmaceutical company dedicated to the development of best-in-class therapies for patients with liver and cardiometabolic diseases who lack optimal treatment options. The company is focused on rapidly advancing its lead candidate, pegozafermin, through clinical development for the treatment of metabolic dysfunction-associated steatohepatitis (MASH) and severe hypertriglyceridemia (SHTG). Pegozafermin is a specifically engineered, potentially best-in-class fibroblast growth factor 21 (FGF21) analog with unique glycoPEGylated technology that optimizes biological activity through an extended half-life. The company is headquartered in San Francisco. For more information, visit www.89bio.com or follow the company on LinkedIn.<br/></p>\n<p><strong>Investor Contact: </strong><br/>Annie Chang <br/>89bio, Inc.<br/>investors@89bio.com<br/><br/><br/><br/></p>\n<p>PJ Kelleher<br/>LifeSci Advisors, LLC<br/>617-430-7579<br/>pkelleher@lifesciadvisors.com<br/><br/><br/></p>\n<p><strong>Media Contact: </strong><br/>Sheryl Seapy<br/>Real Chemistry<br/>sseapy@realchemistry.com<br/><br/><br/></p>\n<br/></body></html>\n<div class=\"bt-text\">\n\n\n<p> 來源：<a href=\"https://finance.yahoo.com/news/89bio-participate-7th-annual-evercore-210500008.html\">GlobeNewswire</a></p>\n<p>為提升您的閱讀體驗，我們對本頁面進行了排版優化</p>\n\n\n</div>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":null,"symbol_name":null,"start_time":0,"source_url":"https://finance.yahoo.com/news/89bio-participate-7th-annual-evercore-210500008.html","article_id":"2486205834","we_media_id":null,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/OBcqXzIqiNQZbGfiTeetOA--~B/aD02ODt3PTE4MTthcHBpZD15dGFjaHlvbg--/https://media.zenfs.com/en/globenewswire.com/b32d53353b31091b62fe237e474ab39c"],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2486205834","pubTimestamp":1732655100,"columns":[],"sourceInfo":{"source_id":"yahoofinance","name":"雅虎金融"},"weMediaInfo":null,"summary":"SAN FRANCISCO, Calif., Nov. 26, 2024  -- 89bio, Inc.  , a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardiometabolic diseases, today announced that the Company’s Management will participate in a fireside chat at the 7th Annual Evercore HealthCONx Conference on Tuesday, December 3, 2024 at 8:20 AM ET and participate in one-on-one investor meetings.The webcast of the fireside chat will be accessible in the investor section of89bio’s website. A replay of the webcast will be available for approximately 30 days following the conference.","collect":0,"end_time":0,"defaultTopTitle":"yahoo.com","property":[],"viewcount":null,"language":"en","relate_stocks":{},"translate_title":"89bio将参加第七届Evercore HealthCONx年会","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ETNB":0.9},"content_text":"SAN FRANCISCO, Calif., Nov. 26, 2024 (GLOBE NEWSWIRE) -- 89bio, Inc. (the “Company” or “89bio”) (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardiometabolic diseases, today announced that the Company’s Management will participate in a fireside chat at the 7th Annual Evercore HealthCONx Conference on Tuesday, December 3, 2024 at 8:20 AM ET and participate in one-on-one investor meetings.\nThe webcast of the fireside chat will be accessible in the investor section of 89bio’s website. A replay of the webcast will be available for approximately 30 days following the conference.\nAbout 89bio89bio is a clinical-stage biopharmaceutical company dedicated to the development of best-in-class therapies for patients with liver and cardiometabolic diseases who lack optimal treatment options. The company is focused on rapidly advancing its lead candidate, pegozafermin, through clinical development for the treatment of metabolic dysfunction-associated steatohepatitis (MASH) and severe hypertriglyceridemia (SHTG). Pegozafermin is a specifically engineered, potentially best-in-class fibroblast growth factor 21 (FGF21) analog with unique glycoPEGylated technology that optimizes biological activity through an extended half-life. The company is headquartered in San Francisco. For more information, visit www.89bio.com or follow the company on LinkedIn.\nInvestor Contact: Annie Chang 89bio, Inc.investors@89bio.com\nPJ KelleherLifeSci Advisors, LLC617-430-7579pkelleher@lifesciadvisors.com\nMedia Contact: Sheryl SeapyReal Chemistrysseapy@realchemistry.com","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1}}}